Compare AU
Compare CURE vs. BCOM
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Global X Bloomberg Commodity Complex ETF (BCOM). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | BCOM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 2 |
Median incremental investment | $619.50 | $3,193.50 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,437.24 | $6,027.49 |
Average age group | > 35 | > 35 |
Key Summary
CURE | BCOM | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | BCOM.AX was created on 2023-07-05 by Global X. The fund's investment portfolio concentrates primarily on broad market commodities. The investment objective of the Fund is to provide investors with a return, that tracks the performance of the Bloomberg Commodity Index Excess Return 3 Month Forward, plus earn interest returns through exposure to cash and/or money market instruments (before fees and expenses). |
Top 3 holdings | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) | GLOBAL X 1-3 Month T-Bill ETF USD Acc (82.82 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | 0.6 % |
Key Summary
CURE | BCOM | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | S&P Biotechnology Select Industry | Bloomberg Commodity Index Excess Return 3 Month Forward - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.6 % |
Price | $51.33 | $10.51 |
Size | $36.301 million | $39.894 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 0.51 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 04/07/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | BCOM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 2 |
Median incremental investment | $619.50 | $3,193.50 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,437.24 | $6,027.49 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | BCOM | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | BCOM |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |